Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PAN 811

Drug Profile

PAN 811

Alternative Names: PAN-811

Latest Information Update: 17 May 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Panacea Pharmaceuticals
  • Class Antidementias; Cytoprotectives; Neuroprotectants; Pyridines; Small molecules; Thiosemicarbazones
  • Mechanism of Action Antioxidants; Chelating agents; Ribonucleotide reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Alzheimer's disease; Stroke

Most Recent Events

  • 16 May 2018 Panacea Pharmaceuticals is now called Sensei Biotherapeutics
  • 07 Nov 2007 Pharmacodynamics data presented at the 37th Annual Meeting of the Society for Neuroscience (SfN-2007) ,
  • 21 Jul 2006 Data presented at the 10th International conference on Alzeimer's Disease and Related Disorders (ICAD-2006) have been added to the Alzheimer's disease pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top